Fuse Biotherapeutics, Inc. — Form D/A
Fuse Biotherapeutics, Inc. of LOS ANGELES, CA, a company, filed a Form D amendment with the SEC on 2021-11-12. The offering totals $9.6M, of which $8.2M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2021-11-12
- Form: D/A
- Accession: 0001871839-21-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $9.6M
- Amount sold: $8.2M
- Remaining: $1.4M
- Investors: 8
- Date of first sale: 2021-06-24
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-405726
Issuer
- Name: Fuse Biotherapeutics, Inc.
- CIK: 0001871839
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 6080 CENTER DRIVE, LOS ANGELES, CA, 90045
- Phone: 3109918254
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Brian Rabinovich | Director | Los Angeles, CA |
| Paul Song | Director | Los Angeles, CA |
| Brian Rabinovich | Executive Officer | Los Angeles, CA |
| Paul Song | Executive Officer | Los Angeles, CA |
| Yuanheng Wang Liang | Director | Los Angeles, CA |
| Jeffrey Takimoto | Executive Officer | Los Angeles, CA |
Other filings by this issuer (2)
More